Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
LPTX
$0.6412
$
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Next Earnings
2026-02-25
Beta
0.086
Average Volume
Market Cap
Last Dividend
CIK
0001509745
ISIN
US52187K2006
CUSIP
52187K101
CEO
Douglas E. Onsi
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
52
IPO Date
2017-01-25
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Leap Therapeutics (NASDAQ:LPTX) and Nemus Bioscience (OTCMKTS:NMUS) Critical Contrast | Nemus Bioscience (OTCMKTS:NMUS - Get Free Report) and Leap Therapeutics (NASDAQ: LPTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk. Profitability This table compares Nemus Bioscience and | Defense World | 2026-01-11 03:20:49 |
| Contrasting Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF) | UCB (OTCMKTS:UCBJF - Get Free Report) and Leap Therapeutics (NASDAQ: LPTX - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Insider and Institutional Ownership 30.5% of Leap Therapeutics shares | Defense World | 2025-12-31 01:49:04 |
| Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) | Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and Vincerx Pharma (NASDAQ: VINC - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Valuation and Earnings This table compares Leap | Defense World | 2025-12-28 02:14:56 |
| Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX) | Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and PaxMedica (NASDAQ: PXMD - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Insider and Institutional Ownership 30.5% of Leap Therapeutics | Defense World | 2025-12-18 03:42:49 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-12 | 2026-02-12 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 8-K | 2025-12-30 | 2025-12-30 | View Filing |
| 8-K | 2025-12-30 | 2025-12-30 | View Filing |
| S-8 | 2025-12-23 | 2025-12-23 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| SC 13D/A | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 3 | 2025-11-21 | 2025-11-21 | View Filing |
| 3 | 2025-11-20 | 2025-11-20 | View Filing |
| 8-K | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| DEFA14A | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 8-K | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13G | 2025-11-18 | 2025-11-18 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 3 | 2025-11-13 | 2025-11-13 | View Filing |
| DEFA14A | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| DEFA14A | 2025-11-03 | 2025-11-03 | View Filing |
| DEF 14A | 2025-11-03 | 2025-11-03 | View Filing |
| PRE 14A | 2025-10-24 | 2025-10-24 | View Filing |
| SC 13D | 2025-10-16 | 2025-10-16 | View Filing |
| 8-K | 2025-10-09 | 2025-10-09 | View Filing |
| 8-K | 2025-10-06 | 2025-10-06 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| ARS | 2025-04-28 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-25 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| S-8 | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-01-28 | 2025-01-28 | View Filing |
| 4 | 2024-11-15 | 2024-11-15 | View Filing |
| 4 | 2024-11-15 | 2024-11-15 | View Filing |
| 4 | 2024-11-15 | 2024-11-15 | View Filing |
| 4 | 2024-11-15 | 2024-11-15 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| S-8 | 2024-11-06 | 2024-11-06 | View Filing |
| SC 13D/A | 2024-10-31 | 2024-10-31 | View Filing |
| SC 13D/A | 2024-10-31 | 2024-10-31 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 30.23% | 0.96 | 39 | 0.33 | 0.17 | 19.21 |
| Gann Fan Strategy | 19.21% | 1 | 18 | 0.24 | 0.18 | 8.19 |
| Swarm Intelligence Strategy | 15.54% | 0.98 | 39 | 0.76 | 0.68 | 17.81 |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | x | xxx |
| xxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |